AU730196C - Aqueous suspension of loteprednol etabonate - Google Patents

Aqueous suspension of loteprednol etabonate

Info

Publication number
AU730196C
AU730196C AU58412/98A AU5841298A AU730196C AU 730196 C AU730196 C AU 730196C AU 58412/98 A AU58412/98 A AU 58412/98A AU 5841298 A AU5841298 A AU 5841298A AU 730196 C AU730196 C AU 730196C
Authority
AU
Australia
Prior art keywords
aqueous suspension
loteprednol etabonate
etabonate
loteprednol
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU58412/98A
Other versions
AU5841298A (en
AU730196B2 (en
Inventor
Katsuhiro Inada
Hideo Terayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of AU5841298A publication Critical patent/AU5841298A/en
Application granted granted Critical
Publication of AU730196B2 publication Critical patent/AU730196B2/en
Publication of AU730196C publication Critical patent/AU730196C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
AU58412/98A 1997-03-14 1998-03-12 Aqueous suspension of loteprednol etabonate Ceased AU730196C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9-82207 1997-03-14
JP8220797 1997-03-14

Publications (3)

Publication Number Publication Date
AU5841298A AU5841298A (en) 1998-09-17
AU730196B2 AU730196B2 (en) 2001-03-01
AU730196C true AU730196C (en) 2001-10-25

Family

ID=13767987

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58412/98A Ceased AU730196C (en) 1997-03-14 1998-03-12 Aqueous suspension of loteprednol etabonate

Country Status (5)

Country Link
US (1) US5916550A (en)
EP (1) EP0868919A3 (en)
KR (1) KR100508227B1 (en)
AU (1) AU730196C (en)
CA (1) CA2231977A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
AU776609B2 (en) 1999-09-24 2004-09-16 Novartis Ag Topical suspension formulations containing ciprofloxacin and dexamethasone
AU2001241045A1 (en) * 2000-03-09 2001-09-17 Kissei Pharmaceutical Co. Ltd. Preventive or therapeutic drugs for eye diseases
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6462033B2 (en) 2000-07-26 2002-10-08 Alcon Universal Ltd. Process for manufacturing compositions containing ciprofloxacin and hydrocortisone
JP4255656B2 (en) * 2001-09-17 2009-04-15 株式会社メニコン Ophthalmic solution and contact lens solution
CN1231218C (en) 2001-09-21 2005-12-14 爱尔康公司 Method of treating middle ear infections
PT1532981E (en) * 2002-08-23 2007-12-12 Santen Pharmaceutical Co Ltd Stable eye drops containing latanoprost as the active ingredient
KR100507794B1 (en) * 2003-02-11 2005-08-17 한미약품 주식회사 Method for preparing concentrated retroviral particle dispersion
WO2004073748A1 (en) * 2003-02-20 2004-09-02 Senju Pharmaceutical Co., Ltd. Aqueous suspension medicine
DE602004025002D1 (en) * 2003-06-19 2010-02-25 Nicholas S Bodor INCREASING THE ACTIVITY AND / OR THE EFFICIENCY OF SOFT STEROIDS WITH ANTI-INFLAMMATORY IMPACT FOR TOPICAL OR LOCAL ADMINISTRATION
DE602004008083T2 (en) * 2003-06-19 2008-04-24 Nicholas S. Gainsville Bodor REINFORCEMENT OF THE ACTIVITY AND / OR DURABILITY OF SELECTED INFLAMMATORY STEROIDS
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
WO2005094836A2 (en) 2004-03-25 2005-10-13 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
WO2006004085A1 (en) * 2004-07-02 2006-01-12 Wakamoto Pharmaceutical Co., Ltd. Water-based medicinal composition containing azithromycin and method of preparing the same
US20100234336A1 (en) * 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
US20070110812A1 (en) * 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
JP2011502989A (en) * 2007-11-01 2011-01-27 ボーシュ アンド ローム インコーポレイティド Non-aqueous water-miscible materials as vehicles for drug delivery
AU2012312816A1 (en) 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5195120A (en) * 1975-02-10 1976-08-20 Tenganekino seizoho
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co An aqueous nasal suspension comprising cyclodextrin

Also Published As

Publication number Publication date
KR19980079771A (en) 1998-11-25
KR100508227B1 (en) 2006-03-23
AU5841298A (en) 1998-09-17
EP0868919A3 (en) 2001-12-19
CA2231977A1 (en) 1998-09-14
AU730196B2 (en) 2001-03-01
US5916550A (en) 1999-06-29
EP0868919A2 (en) 1998-10-07

Similar Documents

Publication Publication Date Title
AU730196C (en) Aqueous suspension of loteprednol etabonate
AU3574897A (en) Aqueous formulations of peptides
AU6883798A (en) Method of anesthesia
AU7552198A (en) Benzylamine derivatives
AU5273398A (en) Atomizer
PL337442A1 (en) Expression adjustment of quinolane phosphoribozyltransferase
AU1242399A (en) Nose sprayer
AU9319798A (en) Reduction of hair growth
HK1026138A1 (en) Aqueous suspension for nasal administration of loteprednol
AU5134599A (en) Expression of functional eukaryotic proteins
AU7175598A (en) Aqueous dispersions of polyamides
AU3290595A (en) An aqueous nasal suspension
AU2091799A (en) Uses of alpha-conotoxin peptides
AU7290898A (en) Preparation of fagopyritols and uses therefor
AU6548598A (en) Enhancement of guar solution stability
AU3145795A (en) Fibrin-cell suspension for construction of new tissue
AU7288998A (en) Aqueous dispersions of polyamides
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU7474998A (en) Haloisoquinoline carboxamide
AU5104396A (en) Aspergillus arabinofuranosidase
AU2241699A (en) Expression of proteolytically-sensitive peptides
AUPO695497A0 (en) End of line pipeliner
AUPO922797A0 (en) Hollow flange section
AU1702499A (en) Recognition e-circuits capable of translation-tolerant recognition
AU8102498A (en) Preparation of diaryl-benzopyrans

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20010123

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20010426